The liver cancer drugs market will register a CAGR of over 10% by 2023

Tuesday, February 5, 2019 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Feb. 4, 2019 /PRNewswire/ -- About this marketLiver cancer is among the leading causes of cancer-related

deaths, globally. The increase in incidence of risk factors like hepatitis B and C and underlying cirrhosis will lead to the rise in risk of liver cancer depending on the etiology. The increase in incidence of life-style diseases like fatty liver is
a major risk factor for liver cancer. Furthermore, the increase in incidence of new risk factors like diabetes, obesity, and related non-alcoholic fatty liver disease may also be associated with the increase in incidence of liver cancer. The current disease management for liver cancer is the same for all patients with different etiologies. Advances in disease management for the causative factors may reduce the incidence of liver cancer. Technavio's analysts have predicted that the liver cancer drugs market will register a CAGR of over 10% by 2023.Read the full report: https://www.reportlinker.com/p05729121 Market OverviewAdvancements in diagnostics methodsLong-term survival requires advanced diagnostic methods, which may detect small tumors that are often present in asymptomatic patients. Elevated levels of the serum marker alfa-fetoprotein are often indicative of the disease when combined with ultrasonography. Liver biopsy is also a diagnostic method used by many professionals. Various serologic markers may help to improve surveillance accuracy. Computed tomography and magnetic resonance imaging are currently used for liver imaging for surveillance. However, they can be used for the diagnosis and staging of liver cancer.Only curative option is surgical resection and transplantationThe surgery is often associated with high recurrence rate of tumors. Patients with recurrent tumors are evaluated for liver transplantation. However, a major challenge for liver transplantation is the number of insufficient donor livers. Another challenge is that the disease is often diagnosed in the advanced stage when surgery or transplantation may not be feasible.For the detailed list of factors that will drive and challenge the growth of the liver cancer drugs market during the 2019-2023, view our report.Competitive LandscapeThe market appears to be concentrated and with the presence of few companies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.Read the full report: https://www.reportlinker.com/p05729121 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Cision View original content:http://www.prnewswire.com/news-releases/the-liver-cancer-drugs-market-will-register-a-cagr-of-over-10-by-2023-300789279.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store